DaVita Inc. (NYSE:DVA) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC lowered its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 28.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 131,548 shares of the company's stock after selling 51,902 shares during the period. Nuveen Asset Management LLC owned approximately 0.16% of DaVita worth $19,673,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Occudo Quantitative Strategies LP bought a new stake in DaVita during the 4th quarter valued at $290,000. NDVR Inc. raised its stake in DaVita by 28.9% during the 4th quarter. NDVR Inc. now owns 1,714 shares of the company's stock valued at $256,000 after acquiring an additional 384 shares in the last quarter. Lighthouse Investment Partners LLC bought a new stake in DaVita during the 4th quarter valued at $1,645,000. Iron Triangle Partners LP bought a new stake in DaVita during the 4th quarter valued at $38,946,000. Finally, Jefferies Financial Group Inc. raised its stake in DaVita by 28.6% during the 4th quarter. Jefferies Financial Group Inc. now owns 174,880 shares of the company's stock valued at $26,153,000 after acquiring an additional 38,855 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

DaVita Price Performance

Shares of DVA traded down $0.57 during midday trading on Thursday, reaching $136.09. The stock had a trading volume of 284,948 shares, compared to its average volume of 870,846. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The company has a market capitalization of $10.28 billion, a P/E ratio of 12.67, a P/E/G ratio of 1.07 and a beta of 1.14. The firm's 50 day moving average price is $144.67 and its 200-day moving average price is $153.13. DaVita Inc. has a 52 week low of $131.76 and a 52 week high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. The business had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The company's quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.26 EPS. On average, analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on DVA. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Sanford C. Bernstein set a $184.00 price objective on DaVita in a research note on Friday, February 21st. Barclays boosted their price objective on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Truist Financial dropped their price objective on DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research note on Monday, May 19th. Finally, Cowen reissued a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $164.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.